Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 404

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630

Open access
Ross, Ruth A, Brockie, Heather C, Stevenson, Lesley A, Murphy, Vicki L, Templeton, Fiona, Makriyannis, Alexandros, Pertwee, Roger G·1999·British Journal of Pharmacology

Abstract

We have tested our prediction that AM630 is a CB 2 cannabinoid receptor ligand and also investigated whether L759633 and L759656, are CB 2 receptor agonists. Binding assays with membranes from CHO cells stably transfected with human CB 1 or CB 2 receptors using [3 H]‐CP55940, confirmed the CB 2‐selectivity of L759633 and L759656 (CB 2/CB 1 affinity ratios=163 and 414 respectively) and showed AM630 to have a Ki at CB 2 receptors of 31.2 n M and a CB 2/CB 1 affinity ratio of 165. In CB 2‐transfected cells, L759633 and L759656 were potent inhibitors of forskolin‐stimulated cyclic AMP production, with EC 50 values of 8.1 and 3.1 n M respectively and CB 1/CB 2 EC 50 ratios of >1000 and >3000 respectively. AM630 inhibited [35 S]‐GTPγS binding to CB 2 receptor membranes (EC 50=76.6 n M), enhanced forskolin‐stimulated cyclic AMP production in CB 2‐transfected cells (5.2 fold by 1 μ M), and antagonized the inhibition of forskolin‐stimulated cyclic AMP production in this cell line induced by CP55940. In CB 1‐transfected cells, forskolin‐stimulated cyclic AMP production was significantly inhibited by AM630 (22.6% at 1 μ M and 45.9% at 10 μ M) and by L759633 at 10 μ M (48%) but not 1 μ M. L759656 (10 μ M) was not inhibitory. AM630 also produced a slight decrease in the mean inhibitory effect of CP55940 on cyclic AMP production which was not statistically significant. We conclude that AM630 is a CB 2‐selective ligand that behaves as an inverse agonist at CB 2 receptors and as a weak partial agonist at CB 1 receptors. L759633 and L759656 are both potent CB 2‐selective agonists. British Journal of Pharmacology (1999) 126, 665–672; doi:10.1038/sj.bjp.0702351

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0702351

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 404

Metadata

Authors
Ross, R. A., Brockie, H. C., Stevenson, L. A., Murphy, V. L., Templeton, F., Makriyannis, A., & Pertwee, R. G.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
1999-02
Volume
126
Issue
3
Pages
665-672
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2062413775
Cited by
404
References
25
FWCI
5.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. https://app.cochat.ai/papers/10.1038/sj.bjp.0702351
The paper
Ross, R. A., Brockie, H. C., Stevenson, L. A., Murphy, V. L., Templeton, F., Makriyannis, A., & Pertwee, R. G. (1999). Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0702351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.